Monoclonal antibody-drug conjugatePhase 3 trialInvestigational
Tisotumab Vedotin
How it works
Binds to Tissue Factor on cancer cells, delivering a toxic payload that kills the cells.
Cancer types
Leukemia— All patients
Efficacy
In clinical trials, around 30% of patients with recurrent or metastatic cervical cancer achieved an objective response, with a median overall survival of approximately 11 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating Tisotumab Vedotin for Solid Tumors | Lung Cancer | phase-2 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.